Effect of thalidomide and rosiglitazone on the prevention of diabetic retinopathy in streptozotocin-induced diabetic rats

Diabetologia

Volumn 46, Issue 12, 2003, Pages 1669-1675

  Bosco, A A ^a,b   Lerario, A C ^a   Santos, R F ^a   Wajchenberg, B L ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Diabetes; Diabetic retinopathy; Rosiglitazone; Thalidomide

Indexed keywords

ROSIGLITAZONE; THALIDOMIDE; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AQUEOUS HUMOR; ARTICLE; CAPILLARY BASEMENT MEMBRANE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC RETINOPATHY; DRUG EFFECT; ELECTRON MICROSCOPY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RETINA CAPILLARY; STREPTOZOCIN DIABETES; THICKNESS; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANIMALS; AQUEOUS HUMOR; CAPILLARIES; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; DISEASE MODELS, ANIMAL; HYPOGLYCEMIC AGENTS; RATS; RATS, SPRAGUE-DAWLEY; RETINAL VESSELS; THALIDOMIDE; THIAZOLIDINEDIONES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 0346846764     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-003-1234-1     Document Type: Article

References (42)

1. Harris MI, Flegal KM, Cowie CC et al. (1998) Prevalence of diabetic, impaired fasting glucose and impaired glucose tolerance in U.S. adults. Diabetes Care 21:518-524
2. Merimee TJ (1990) Diabetic retinopathy: a synthesis of perspectives. N Engl J Med 322:978-983
3. Charles MC Jr, Lee DA (1995) Prevention and treatment of the complications of diabetes mellitus. N Engl J Med 332:1210-1217
4. DCCT Reseach Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent Diabetes Mellitus. N Engl J Med 329:977-986
5. Imesch PD, Bindley CD, Wallow IHL (1997) Clinicopathologic correlation of intraretinal microvascular abnormalities. Retina 17:321-329
6. Ishibashi T, Inomato H (1993) Ultrastructure of retinal vessels in diabetic patients. Br J Ophthalmol 77:574-578
7. Lu M, Kuroki M, Amano S et al. (1998) Advanced glycation and products increase retinal vascular endothelial growth factor expression. J Clin Invest 101:1219-1224
8. Cavallo MG, Pozzilli P, Bird C (1991) Cytokines in sera from insulin-dependent diabetic patients at diagnosis. Clin Exp Immunol 68:256-259
9. Murata T, Nakagawa K, Khalil A, Ishibashi I, Inomata H, Sueishi K (1996) The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas. Lab Invest 74:819-825
10. Paques M, Massin P, Gaudric A (1997) Growth factors and diabetic retinopathy. Diabetes Metab 23:152-60
11. Frank RN (1994) Vascular endothelial growth factor - its role in retinal vascular proliferation. N Engl J Med 331:1519-1520
12. Aiello LP, Avery RL, Arrigg PG et al. (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480-1487
13. Tanaka Y, Katoh S, Hori S, Miura M, Yamashita H (1997) Vascular endothelial growth factor in diabetic retinopathy. Lancet 349:1520-1526
14. Clermont AC, Aiello LP, Mori F, Aiello LM, Bursell SE (1997) Vascular endothelial growth factor and severity of nonproliferative diabetic retinopathy mediate retinal hemodynamics in vivo: a potential role for vascular endothelial growth factor in the progression of nonproliferative diabetic retinopathy. Am J Ophthalmol 124:433-446
15. Aiello LP, Pierce EA, Foley ED et al. (1995) Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 92: 10457-10461
16. Miyamoto K, Khosrol S, Bursell SE et al. (1999) Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci USA 96:10836-10841
17. Schröder S, Palinski W, Schmid-Schönbein S (1991) Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy. Am J Pathol 139:81-98
18. McLeod DS, Lefer DJ, Merges C, Lutty GA (1995) Enhanced expression of intracellular adhesion molecule-1 and P-selection in the diabetic human retina and choroid. Am J Pathol 147:642-653
19. Barouch FC, Miyamoto K, Allport JR et al. (2000) Integrin-mediated neutrophil adhesion and retinal leukostasis in diabetes. Invest Ophthalmol Vis Sci 41:1153-1158
20. Engerman RL, Kern TS (1995) Retinopathy in animal models of diabetes. Diabetes Metab Rev 11:109-120
21. Wallow IHL, Engerman RL (1977) Permeability and patency of retinal blood vessels in experimental diabetes. Invest Ophthalmol Vis Sci 16:447-461
22. Hirschi KK, D'Amore PA (1997) Control of angiogenesis by the pericyte: molecular mechanisms and significance. Exs 79:419-428
23. Amato RJ, Loughnan MS, Flynn E, Folkman J (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91:4082-4085
24. Murata T, He S, Hangai M et al. (2000) Peroxisome proliferator-activated receptor {gamma} ligands inhibit choroidal neovascularization. Invest Ophthalmol Vis Sci 41:2309-2317
25. Xin X, Yang S, Kowalski J, Gerritsen ME (1999) Peroxisome proliferator-activated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 274:9116-9121
26. Murata T, Hata Y, Ishibashi T, Kim S, Law RE (2001) Response of experimental retinal neovascularization to thiazolidinediones Arch Ophthalmol 119:709-717
27. Ghigliotti G, Repetto T, Farris A, Roy MT, De Marchi R (1993) Thalidomide: treatment of choice for aphthous ulcers in patients seropositive for human immunodeficiency virus. J Am Acad Dermatol 28:271-272
28. Raje N, Anderson K (1999) Thalidomide - a revival story. N Engl J Med 341:1606-1609
29. Oliver SJ, Cheng TP, Banquerigo ML, Brahn E (1998) The effect of thalidomide and 2 analogs on collagen induced arthritis. J Rheumatol 25:964-969
30. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G (1991) Thalidomide selectively inhibits tumor necrosis factor alfa production by stimulated human monocytes. J Exp Med 173:699-703
31. Jiang C, Ting AT, Seed B (1998) PPAR-γ agonists inhibit production of inflammatory cytokines. Nature 301:82-86
32. Goetze S, Xi XP, Kawano H et al. (1999) PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells. J Cardiovasc Pharmacol 33:798-806
33. Young PW, Cawthone MA, Coyle PJ et al. (1995) Reapet treatment of obese mice with BRL-49653, a new potent insulin sensitizer, enhances insulin action in white adipocytes. Association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling. Diabetes 44:1087-1092
34. Chiarelli F, Spagnoli A, Basciani F et al. (2000) Vascular endothelial growth factor (VEGF) in children, adolescents and young adults with type 1 diabetes mellitus: relation to glycemic control and microvascular complications. Diabetic Med 17:650-656
35. Spoerri PE, Robison Jr WG, Player D et al. (1998) Diabetes related increase in plasminogen activator inhibitor 1 expression in monkey retinal capillaries. Int Diabetes 6: 15-27
36. Roy S, Sala R, Cagliero E, Lorenzi M (1990) Overexpression of fibronectin induced by diabetes or high glucose: phenomenon with a memory. Proc Natl Acad Sci USA 87:404-408
37. Bauer KS, Dixon SC, Figg WD (1998) Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol 55: 1827-1834
38. Calabrese L, Fleischer AB (2000) Thalidomide: current and potential clinical applications. Am J Med 108:487-495
39. Grant MB, Spoerri PE, Player DW et al. (2000) Plasminogen activator inhibitor (PAI)-1 overexpression in retinal microvessels of PAI-1 transgenic mice. Invest Ophthalmol Vis Sci 41:2296-2303
40. Walker AB, Naderali EK, Chattington PD, Buckingham RE, Williams G (1998) Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro. Diabetes 47:810-814
41. Walker AB, Chattington PD, Buckingham RE, Williams G (1999) The thiazolidinedione rosiglitazone (BRL 49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes 48:1448-1453
42. Emoto M, Anno T, Sato Y et al. (2001) Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-11 adipocytes. Diabetes 50:1166-1170